[{"id":"cccc4a07-4111-4690-8a6c-b11f8091dbca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03082209","created_at":"2021-01-18T15:11:02.815Z","updated_at":"2024-07-02T16:35:59.314Z","phase":"Phase 1","brief_title":"A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies","source_id_and_acronym":"NCT03082209","lead_sponsor":"AbbVie","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 03/20/2017","start_date":" 03/20/2017","primary_txt":" Primary completion: 01/21/2022","primary_completion_date":" 01/21/2022","study_txt":" Completion: 01/21/2022","study_completion_date":" 01/21/2022","last_update_posted":"2022-12-09"}]